General Biologicals (ROCO:4117) Other Financing: NT$139.3 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4117 General Biologicals Corp ROCO:4117
50 GF Score
Price NT$10.95
GF Value NT$14.06
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is General Biologicals Other Financing?

General Biologicals ROCO:4117 +5.29% 50 Other Financing is NT$139.3 Mil as of Dec. 2025. GuruFocus rates ROCO:4117 with a GF Score™ of 50/100 and a GF Value™ of NT$14.06 (Modestly Undervalued). The stock has 8 warning signs investors should review.

General Biologicals's Other Financing for the six months ended in Dec. 2025 was NT$120.3 Mil.

General Biologicals's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$139.3 Mil.

General Biologicals Other Financing Historical Data

* Premium members only.

The historical data trend for General Biologicals's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

General Biologicals Other Financing Chart

General Biologicals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 19.34

General Biologicals Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 19.04 120.30
ROCO:4117
50GF Score
General Biologicals Corp ROCO:4117
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

General Biologicals Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$139.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$139.3 Mil mean?
General Biologicals (ROCO:4117) has a Other Financing of NT$139.3 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for General Biologicals and its competitors.
Is General Biologicals' Other Financing too high?
General Biologicals' current Other Financing is NT$139.3 Mil. Overall, General Biologicals has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' Other Financing compare to ZTS and UTHR?
General Biologicals' Other Financing of NT$139.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for General Biologicals and its competitors. General Biologicals's current Other Financing is NT$139.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.06, compared to a current price of NT$10.95 — trading 22.1% below its estimated fair value. The current Other Financing is NT$139.3 Mil. General Biologicals' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current Other Financing is NT$139.3 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is General Biologicals (ROCO:4117) Overvalued in 2026?

Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued. The current stock price of NT$10.95 is trading 22.1% below its estimated GF Value™ of NT$14.06. GuruFocus considers General Biologicals to be Modestly Undervalued.

Key valuation signals for ROCO:4117:

  • Other Financing: NT$139.3 Mil
  • GF Value™: NT$14.06 vs. price of NT$10.95 (22.1% below fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

General Biologicals Business Description

Address No-6, Innovation First Road, Hsinchu Science Park, Hsinchu, TWN, 300092
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
50GF Score

Get the complete analysis for ROCO:4117

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.95
Price
NT$14.06
GF Value